GP6

Across TCGA pan-cancer cohorts, GP6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GP6 data layer compared with 23 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GP6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GP6 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

LUAD, LSCC, and PDAC are the cancer types where GP6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.419	0.748	.009	20	view →
LSCC	OS	Median	All	0.945	1.000	.031	4	view →
PDAC	DFS	Median	All	0.832	0.591	.021	3	view →
CCRCC	DFS	Median	All	0.908	0.539	.044	2	view →
GBM	DFS	Median	All	0.672	0.911	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GP6–LUAD (DFS)

Open the LUAD breakdown →